Formålet med studien: This phase II trial investigates the efficacy and safety of dabrafenib and trametinib treatment in patients with Erdheim Chester disease that have BRAF V600 gene mutations.
Sponsor: National Cancer Institute (NCI)
Kontaktopplysninger for rettssaken: Study Coordinator: Ms. Abha Adat, aadat@mdanderson.org, or the Principal Investigator Filip Janku, 713-563-1930, FJanku@mdanderson.org.
Ønsket pasientmedvirkning: ECD patients with BRAF V600 mutation who have not previously been treated with a BRAF- or MEK-inhibitor and are 18-years or older.
Kjente sentre som tar imot ECD-pasienter i studien: MD Anderson, Houston, Texas
ClinicalTrials.gov-identifikator: NCT03794297

